Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$4.11 +0.7%	$3.89	$2.55 ▼ $6.42	$203.91M	1.14	3,893 shs	3,985 shs
IMTX Immatics	$5.90 -3.3%	$6.03	$3.30 ▼ $13.09	$741.46M	0.93	500,044 shs	791,338 shs
NRIX Nurix Therapeutics	$10.56 -0.1%	$11.70	$8.18 ▼ $29.56	$808.07M	2.14	709,874 shs	373,576 shs
PROK ProKidney	$2.42 +2.1%	$2.12	$0.46 ▼ $7.13	$693.69M	1.76	3.63 million shs	2.43 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	+3.53%	+7.87%	+8.62%	-1.91%	+3.01%
IMTX Immatics	-3.28%	-6.65%	-1.01%	+24.47%	-49.62%
NRIX Nurix Therapeutics	-0.09%	+4.87%	-13.09%	+10.46%	-51.82%
PROK ProKidney	+2.11%	-5.84%	-28.19%	+200.02%	+6.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	2.1281 of 5 stars	3.5	3.0	3.3	0.0	0.0
IMTX Immatics	2.2506 of 5 stars	3.6	3.0	1.7	1.7	0.0
NRIX Nurix Therapeutics	2.568 of 5 stars	4.4	2.0	2.2	0.8	0.0
PROK ProKidney	3.3941 of 5 stars	3.2	4.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$13.00	216.30% Upside
IMTX Immatics	3.20	Buy	$14.67	148.59% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	173.36% Upside
PROK ProKidney	2.40	Hold	$6.25	158.26% Upside

Current Analyst Ratings Breakdown

Latest GNFT, PROK, NRIX, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.68	$0.07 per share	58.30	$1.50 per share	2.74
IMTX Immatics	$168.65M	4.25	$0.24 per share	24.97	$5.12 per share	1.15
NRIX Nurix Therapeutics	$54.55M	14.80	N/A	N/A	$7.44 per share	1.42
PROK ProKidney	$80K	8,854.18	N/A	N/A	($3.42) per share	-0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-59.29%	-15.54%	-12.11%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	8/15/2025 (Estimated)

Latest GNFT, PROK, NRIX, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	IMTX Immatics	-$0.38	-$0.66	-$0.28	-$0.66	$13.05 million	$6.48 million
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
IMTX Immatics	N/A	10.28	10.28
NRIX Nurix Therapeutics	N/A	6.82	6.82
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
IMTX Immatics	64.41%
NRIX Nurix Therapeutics	N/A
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
IMTX Immatics	3.30%
NRIX Nurix Therapeutics	7.40%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IMTX Immatics	260	121.55 million	117.54 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

GNFT, PROK, NRIX, and IMTX Headlines

Recent News About These Companies

ProKidney Reports 78 Percent Gain in Q2

August 14 at 10:16 PM | theglobeandmail.com

Citi Reaffirms Their Buy Rating on ProKidney (PROK)

August 14 at 10:16 PM | theglobeandmail.com

ProKidney reports larger second-quarter loss as key studies continue

August 14 at 10:16 PM | journalnow.comJ

ProKidney Corp. Reports Q2 2025 Financial Results

August 13 at 7:12 AM | msn.com

ProKidney reports Q2 EPS (13c), consensus (14c)

August 12 at 9:05 PM | msn.com

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12 at 4:01 PM | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts

August 10, 2025 | marketbeat.com

ProKidney Corp. (PROK) - Yahoo Finance

August 9, 2025 | finance.yahoo.com

ProKidney Corp. (NASDAQ:PROK) Given Average Recommendation of "Hold" by Brokerages

August 9, 2025 | americanbankingnews.com

ProKidney And 2 Other Penny Stocks To Watch Closely

August 7, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading Down 10.5% - What's Next?

August 7, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?

August 1, 2025 | marketbeat.com

ProKidney (PROK) to Release Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?

July 29, 2025 | marketbeat.com

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed

July 25, 2025 | rhinotimes.comR

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

July 22, 2025 | msn.com

Meet the Biotech Stock That Rocketed 775% Higher

July 22, 2025 | fool.com

ProKidney (NASDAQ:PROK) Shares Gap Up - Here's Why

July 21, 2025 | marketbeat.com

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

July 20, 2025 | insidermonkey.com

ProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?

July 18, 2025 | marketbeat.com

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 17, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, PROK, NRIX, and IMTX Company Descriptions

GENFIT NASDAQ:GNFT

$4.11 +0.03 (+0.74%)

Closing price 08/14/2025 03:46 PM Eastern

Extended Trading

$4.21 +0.10 (+2.41%)

As of 08:01 AM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Immatics NASDAQ:IMTX

$5.90 -0.20 (-3.28%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$5.95 +0.05 (+0.86%)

As of 07:00 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Nurix Therapeutics NASDAQ:NRIX

$10.56 -0.01 (-0.09%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$10.40 -0.16 (-1.51%)

As of 08/14/2025 04:38 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

ProKidney NASDAQ:PROK

$2.42 +0.05 (+2.11%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.35 -0.07 (-2.73%)

As of 08:10 AM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time